Mont-Saint-Guibert, Belgium, –Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces today the publication of its first Letter to Shareholders.
In this first issue, Cardio3 BioSciences takes stock of its activities in 2013 and early 2014 and looks in detail at cardiopoiesis, its proprietary cell programming platform. It also features an interview with Dr William Wijns, who looks at cell regeneration, and the similarities and differences between the Cardio3 BioSciences technology and the work of Professor Yamanaka, who won the Nobel Prize in Medicine in 2012.
Visit the Cardio3 BioSciences website at www.c3bs.com or follow this link http://www.c3bs.com/en/letter-shareholders-february-2014 to go straight to the Cardio3 BioSciences Letter to Shareholders.
